| Not Yet Recruiting | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications NCT07240649 | Jay C. Buckey Jr. | Phase 4 |
| Active Not Recruiting | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products NCT05476926 | Hoffmann-La Roche | — |
| Completed | Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO NCT04793100 | Fondation Ophtalmologique Adolphe de Rothschild | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Centr NCT04740931 | Hoffmann-La Roche | Phase 3 |
| Completed | 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) NCT04667910 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Unknown | Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. NCT04601701 | He Eye Hospital | N/A |
| Completed | Treatment of Central Retinal Vein Occlusion Using Stem Cells Study NCT03981549 | The Emmes Company, LLC | Phase 1 / Phase 2 |
| Terminated | Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to NCT03810313 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | Surgical Stabilizer Assisted RVC With rtPA for CRVO NCT03417401 | Universitaire Ziekenhuizen KU Leuven | Phase 1 |
| Completed | Phase I RVC With Ocriplasmin for CRVO NCT02747030 | Universitaire Ziekenhuizen KU Leuven | Phase 1 |
| Completed | Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO NCT02800642 | Bayer | Phase 4 |
| Completed | Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion NCT03223714 | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 |
| Completed | Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO NCT02503540 | Justis Ehlers | Phase 4 |
| Unknown | Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients NCT02405741 | Assaf-Harofeh Medical Center | Phase 2 |
| Completed | Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend R NCT02274259 | Anders Kvanta | Phase 4 |
| Completed | Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study NCT02390245 | Wills Eye | N/A |
| Completed | Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) NCT01969708 | The Emmes Company, LLC | Phase 3 |
| Unknown | Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I NCT02173873 | Rafic Hariri University Hospital | Phase 1 |
| Unknown | Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occ NCT02169648 | Tokyo Medical University | N/A |
| Unknown | Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO NCT02091505 | Mie University | N/A |
| Completed | Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) NCT01976312 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion NCT01827722 | Valley Retina Institute | Phase 4 |
| Completed | Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study NCT01793181 | St. Erik Eye Hospital | — |
| Completed | Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion NCT01724554 | Ophthalmic Consultants of Boston | Phase 1 / Phase 2 |
| Completed | Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival NCT01640171 | Retina Vitreous Associates of Florida | N/A |
| Unknown | Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Livin NCT01348633 | University of Toronto | — |
| Completed | Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Centr NCT01535261 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion NCT01581411 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab NCT01471691 | Hanscom, Thomas, M.D. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patien NCT01396083 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye NCT01531842 | Mid Atlantic Retina | N/A |
| Unknown | Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion NCT01303276 | University of Toronto | — |
| Completed | Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab NCT01360385 | Glostrup University Hospital, Copenhagen | — |
| Completed | Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema NCT01231633 | Long Island Vitreoretinal Consultants | N/A |
| Unknown | Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) NCT01178697 | Shahid Beheshti University of Medical Sciences | Phase 2 |
| Completed | Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion NCT01028248 | California Retina Consultants | Phase 1 |
| Completed | Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion NCT01448018 | Centre Hospitalier Intercommunal Creteil | Phase 4 |
| Unknown | Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion NCT01011374 | Retina Associates of Cleveland, Inc | Phase 1 |
| Terminated | Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients Wi NCT00969293 | Fovea Pharmaceuticals SA | Phase 1 |
| Completed | Bevacizumab for Central Retinal Vein Occlusion Study NCT00906685 | Anders Kvanta | Phase 3 |
| Unknown | Atorvastatin for the Treatment of Retinal Vein Occlusion NCT00517257 | University of Toronto | Phase 3 |
| Terminated | Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO NCT00566761 | Asociación para Evitar la Ceguera en México | Phase 4 |
| Completed | A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO NCT00567697 | Aleris Helse | Phase 3 |
| Terminated | Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusion NCT00500045 | Palo Alto Medical Foundation | Phase 2 / Phase 3 |
| Completed | A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging NCT00556114 | University of California, Irvine | — |
| Unknown | Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion NCT00383773 | Hadassah Medical Organization | N/A |
| Completed | Lucentis for Central Retinal Vein Occlusion (CRVO) NCT00406796 | California Retina Consultants | Phase 1 |
| Unknown | The Effectiveness of Intravitreal Avastin Injection for CRVO NCT01678248 | Ziv Hospital | — |
| Completed | The ROVO Study: Radial Optic Neurotomy for CVO NCT00532142 | Rudolf Foundation Clinic | Phase 2 / Phase 3 |
| Completed | A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion NCT00952614 | Glenn Jaffe | N/A |
| Terminated | Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). NCT00211471 | Manhattan Eye, Ear & Throat Hospital | Phase 2 |